Patents Assigned to i2o Therapeutics, Inc.
  • Patent number: 11840559
    Abstract: This invention relates to isolated polypeptides that are glucagon-receptor selective analogs and peptide derivatives thereof. These analogs are selective for human glucagon receptor with improved solubility, thermal stability, and physicochemical properties as compared to native endogenous glucagon. This invention also relates to methods of using such polypeptides in a variety of therapeutic and diagnostic indications, as well as methods of producing such polypeptides. These analogs are useful, alone or in combination with other therapeutic peptides, in methods of treating obesity, diabetes, metabolic disorders, and other disorders or disease.
    Type: Grant
    Filed: November 30, 2021
    Date of Patent: December 12, 2023
    Assignee: i2o Therapeutics, Inc.
    Inventors: William Blackwell, Ved P. Srivastava, Mark A. Paulik, Andrew Young, Robert Neil Hunter, III, Steven Thomas Dock